Agios Pharmaceuticals, Inc is a biotechnology business based in the US. Agios Pharmaceuticals shares (AGIO.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $35.28 – an increase of 0.34% over the previous week. Agios Pharmaceuticals employs 536 staff and has a trailing 12-month revenue of around $194.6 million.
Since the stock market crash in March caused by coronavirus, Agios Pharmaceuticals's share price has had significant negative movement.
Its last market close was $35.28, which is 33.57% down on its pre-crash value of $53.11 and 27.03% up on the lowest point reached during the March crash when the shares fell as low as $27.774.
If you had bought $1,000 worth of Agios Pharmaceuticals shares at the start of February 2020, those shares would have been worth $686.25 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $711.24.
|Latest market close||$35.28|
|52-week range||$27.774 - $56.75|
|50-day moving average||$40.7265|
|200-day moving average||$42.5999|
|Wall St. target price||$62.91|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-6.673|
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
|1 week (2021-01-08)||-24.94%|
|1 month (2020-12-16)||1.09%|
|3 months (2020-10-16)||-4.10%|
|6 months (2020-07-16)||-33.68%|
|1 year (2020-01-16)||-33.27%|
|2 years (2019-01-16)||-38.79%|
|3 years (2018-01-16)||-50.00%|
|5 years (2016-01-15)||-31.68%|
|Revenue TTM||$194.6 million|
|Gross profit TTM||$-294,299,000|
|Return on assets TTM||-25.64%|
|Return on equity TTM||-71.51%|
|Market capitalisation||$3.1 billion|
TTM: trailing 12 months
There are currently 5.4 million Agios Pharmaceuticals shares held short by investors – that's known as Agios Pharmaceuticals's "short interest". This figure is 9.6% up from 5.0 million last month.
There are a few different ways that this level of interest in shorting Agios Pharmaceuticals shares can be evaluated.
Agios Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Agios Pharmaceuticals shares currently shorted divided by the average quantity of Agios Pharmaceuticals shares traded daily (recently around 752696.12188366). Agios Pharmaceuticals's SIR currently stands at 7.22. In other words for every 100,000 Agios Pharmaceuticals shares traded daily on the market, roughly 7220 shares are currently held short.
However Agios Pharmaceuticals's short interest can also be evaluated against the total number of Agios Pharmaceuticals shares, or, against the total number of tradable Agios Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Agios Pharmaceuticals's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 Agios Pharmaceuticals shares in existence, roughly 80 shares are currently held short) or 0.1214% of the tradable shares (for every 100,000 tradable Agios Pharmaceuticals shares, roughly 121 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Agios Pharmaceuticals.
Find out more about how you can short Agios Pharmaceuticals stock.
We're not expecting Agios Pharmaceuticals to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.
Over the last 12 months, Agios Pharmaceuticals's shares have ranged in value from as little as $27.774 up to $56.75. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Agios Pharmaceuticals's is 1.8094. This would suggest that Agios Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of hematologic malignancies, solid tumors, and rare genetic diseases. The company offers TIBSOVO (ivosidenib), an oral targeted inhibitor for treating adult patients with relapsed or refractory acute myeloid leukemia (R/R AML), as well as to treat patients with newly diagnosed AML; and IDHIFA, an oral targeted inhibitor for patients with R/R AML and an isocitrate dehydrogenase 2 mutation. It is also developing TIBSOVO, which has completed Phase II clinical trials to treat IC eligible frontline AML; that is in Phase III clinical trials for treating IC ineligible frontline AML; and that is in Phase III clinical trials for the treatment of cholangiocarcinoma, as well as in early stage clinical development to treat glioma and solid tumors. In addition, the company is developing IDHIFA, which has completed Phase II clinical study for treating IC eligible frontline AML; and that is in Phase I/II clinical trials for the treatment of IC ineligible frontline AML. Further, it is developing mitapivat, which is in Phase III clinical trials to treat pyruvate kinase deficiency, as well as in Phase II clinical study for treating thalassemia; vorasidenib (AG-881) that is in Phase I clinical trials for the treatment of solid tumors, including glioma; AG-270, which is in Phase I dose-escalation trial to treat methylthioadenosine phosphorylase deleted cancers; and AG-636 that is in pre-clinical stage for treating hematologic malignancies. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is based in Cambridge, Massachusetts.
Learn more about Transportation and Logistics Systems’ recent performance and where you can invest in Transportation and Logistics Systems shares. We also run through some helpful rules of thumb for any investor.
Learn more about Charlie’s Holdings’ recent performance and where you can invest in Charlie’s Holdings shares. We also run through some helpful rules of thumb for any investor.
Learn more about Lemonade’s recent performance and where you can invest in Lemonade shares. We also run through some helpful rules of thumb for any investor.
Learn more about Unity Software’s recent performance and where you can invest in Unity Software shares. We also run through some helpful rules of thumb for any investor
Learn more about FuelCell Energy’s recent performance and where you can invest in FuelCell Energy shares. We also run through some helpful rules of thumb for any investor.
Learn more about CloudCommerce’s recent performance and where you can invest in CloudCommerce shares. We also run through some helpful rules of thumb for any investor
Ever wondered how to buy shares in Zomedica Pharmaceuticals? We explain how and compare a range of providers that can give you access to many brands, including Zomedica Pharmaceuticals.
Ever wondered how to buy shares in YRC Worldwide? We explain how and compare a range of providers that can give you access to many brands, including YRC Worldwide.
Ever wondered how to buy shares in Xeros Technology Group? We explain how and compare a range of providers that can give you access to many brands, including Xeros Technology Group.
Ever wondered how to buy shares in Xpediator? We explain how and compare a range of providers that can give you access to many brands, including Xpediator.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.